# Gustavo Helguera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7903484/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 53 papers | 3,005 citations | 218677 26 h-index | 223800 46 g-index |
| 60 all docs | 60 docs citations | 60 times ranked | 4830 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nature Communications, 2022, 13, 558. | 12.8 | 4 |
| 2 | Large Area Microfluidic Bioreactor for Production of Recombinant Protein. Biosensors, 2022, 12, 526. | 4.7 | 2 |
| 3 | Antibody-Based Inhibition of Pathogenic New World Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of the Human Transferrin Receptor 1 Apical Domain. Journal of Virology, 2021, 95, e0186820. | 3.4 | 7 |
| 4 | Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein. Cytokine, 2019, 120, 220-226. | 3.2 | 4 |
| 5 | Production of monoclonal antibodies in microfluidic devices. Integrative Biology (United Kingdom), 2018, 10, 136-144. | 1.3 | 9 |
| 6 | Sub-Ã¥ngstrÃ¶m cryo-EM structure of a prion protofibril reveals a polar clasp. Nature Structural and Molecular Biology, 2018, 25, 131-134. | 8.2 | 87 |
| 7 | Development of image analysis software for quantification of viable cells in microchips. PLoS ONE, 2018, 13, e0193605. | 2.5 | 8 |
| 8 | Antibody-mediated targeting of the transferrin receptor in cancer cells. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico, 2016, 73, 372-379. | 0.3 | 44 |
| 9 | Evaluation of cell culture in microfluidic chips for application in monoclonal antibody production. Microelectronic Engineering, 2016, 158, 126-129. | 2.4 | 21 |
| 10 | Antibody-mediated targeting of the transferrin receptor in cancer cells. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico (English Edition), 2016, 73, 372-379. | 0.0 | 0 |
| 11 | Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 902-915. | 4.1 | 36 |
| 12 | Paclitaxel-loaded PCLâ€“TPGS nanoparticles: In vitro and in vivo performance compared with AbraxaneÂ®. Colloids and Surfaces B: Biointerfaces, 2014, 113, 43-50. | 5.0 | 101 |
| 13 | A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer, 2013, 13, 195. | 2.6 | 34 |
| 14 | Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. Journal of Controlled Release, 2013, 171, 322-329. | 9.9 | 42 |
| 15 | Adaptive Downregulation of Mitochondrial Function in Down Syndrome. Cell Metabolism, 2013, 17, 132-140. | 16.2 | 130 |
| 16 | Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicology in Vitro, 2013, 27, 220-231. | 2.4 | 32 |
| 17 | â€œTrueâ€•Hydrophilic-Lipophilic Balance of Polyoxyethylene Fatty Acid Esters Nonionic Surfactants. Journal of Dispersion Science and Technology, 2013, 34, 716-721. | 2.4 | 2 |
| 18 | IBCâ€™s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5â€“8, 2011, San Diego, CA. MAbs, 2012, 4, 153-181. | 5.2 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | An Antibody Recognizing the Apical Domain of Human Transferrin Receptor 1 Efficiently Inhibits the Entry of All New World Hemorrhagic Fever Arenaviruses. Journal of Virology, 2012, 86, 4024-4028. | 3.4 | 47 |
| 20 | The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 291-317. | 2.4 | 610 |
| 21 | Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunology, Immunotherapy, 2012, 61, 991-1003. | 4.2 | 37 |
| 22 | Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia and Lymphoma, 2011, 52, 2169-2178. | 1.3 | 20 |
| 23 | An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies. Journal of Immunotherapy, 2011, 34, 500-508. | 2.4 | 28 |
| 24 | Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. Journal of Immunological Methods, 2011, 368, 54-63. | 1.4 | 14 |
| 25 | Inhibition of NF-Î²B and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. International Journal of Oncology, 2010, 36, 1299-307. | 3.3 | 11 |
| 26 | The IgE Antibody and Its Use in Cancer Immunotherapy. , 2010, , 159-183. | | 4 |
| 27 | Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19322-19327. | 7.1 | 66 |
| 28 | Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition. Physiological Genomics, 2009, 36, 89-97. | 2.3 | 27 |
| 29 | A versatile targeting system with lentiviral vectors bearing the biotinâ€adaptor peptide. Journal of Gene Medicine, 2009, 11, 655-663. | 2.8 | 45 |
| 30 | Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia, 2009, 23, 59-70. | 7.2 | 42 |
| 31 | Bihelical waves: A novel form of eukaryotic cell motility exhibited by African trypanosomes. Biophysical Journal, 2009, 96, 631a. | 0.5 | 0 |
| 32 | Antibodyâ€“cytokine fusion proteins: applications in cancer therapy. Expert Opinion on Biological Therapy, 2008, 8, 609-632. | 3.1 | 45 |
| 33 | A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Molecular Cancer Therapeutics, 2008, 7, 721-729. | 4.1 | 10 |
| 34 | Targeting the Transferrin Receptor to Overcome Resistance to Anti-Cancer Agents. , 2008, , 13-27. | | 2 |
| 35 | Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis. Blood, 2008, 112, 4473-4473. | 1.4 | 0 |
| 36 | Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance. Blood, 2008, 112, 3770-3770. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Cellular and Molecular Mechanisms of Sensitivity and Resistance of Hematopoietic Malignant Cells to Treatment with ch128.1Av, An Antibody-Avidin Fusion Protein Specific for Human Transferrin Receptor 1 (CD71).. Blood, 2008, 112, 1608-1608. | 1.4 | 0 |
| 38 | Conjugation of an antiâ€“transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Molecular Cancer Therapeutics, 2007, 6, 2995-3008. | 4.1 | 38 |
| 39 | Binding specificity and internalization properties of an antibodyâ€“avidin fusion protein targeting the human transferrin receptor. Journal of Controlled Release, 2007, 124, 35-42. | 9.9 | 29 |
| 40 | Long-term immunity elicited by antibodyâ€“cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunology, Immunotherapy, 2007, 56, 1507-1512. | 4.2 | 8 |
| 41 | Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine, 2006, 24, 304-316. | 3.8 | 23 |
| 42 | Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood, 2006, 108, 2745-2754. | 1.4 | 50 |
| 43 | The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clinical Immunology, 2006, 121, 159-176. | 3.2 | 462 |
| 44 | The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology, 2006, 121, 144-158. | 3.2 | 525 |
| 45 | Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Molecular Cancer Therapeutics, 2006, 5, 1029-1040. | 4.1 | 27 |
| 46 | Antibodyâ€“Cytokine Fusion Proteins for the Therapy of Cancer. , 2005, 109, 347-374. | | 16 |
| 47 | Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy. FEBS Letters, 2005, 579, 4856-4860. | 2.8 | 47 |
| 48 | Antibody-Cytokine Fusion Proteins: Harnessing the Combined Power of Cytokines and Antibodies for Cancer Therapy. Clinical Immunology, 2002, 105, 233-246. | 3.2 | 28 |
| 49 | Tissue-specific regulation of Ca2+ channel protein expression by sex hormones. Biochimica Et Biophysica Acta - General Subjects, 2002, 1569, 59-66. | 2.4 | 39 |
| 50 | Remodeling of Kv4.3 Potassium Channel Gene Expression under the Control of Sex Hormones. Journal of Biological Chemistry, 2001, 276, 31883-31890. | 3.4 | 112 |
| 51 | Phosphoryl Group Exchange between ATP and ADP Catalyzed by H+-ATPase from Oat Roots. Plant Physiology, 1997, 114, 1397-1403. | 4.8 | 1 |
| 52 | ATP activation of plasma membrane yeast H+-ATPase shows complex kinetics independently of the degree of purification. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1153, 283-288. | 2.6 | 6 |
| 53 | Biosimilar Monoclonal Antibodies in Latin America. , 0, , . | | 2 |